BioSpace News Archive

Kantaro Biosciences, LLC (“Kantaro”), a joint venture between the Mount Sinai Health System and RenalytixAI plc (LSE: RENX / NASDAQ: RNLX), and manufacturing partner Bio-Techne Corporation (NASDAQ: TECH), entered into a two-year marketing and distribution agreement with EKF Diagnostics, a global leader in diagnostic testing.

Data presented by Invitae (NYSE: NVTA), a leading medical genetics company, at the American Society of Human Genetics (ASHG) Virtual Meeting found one in ten men with prostate cancer harbor genetic changes linked to hereditary cancer syndromes and three-quarters of those patients met criteria for changes in cancer management or treatment based on their genetic findings.

Synchron, a neurovascular bioelectronics medicine company, today announced publication of a first-in-human study demonstrating successful use of the Stentrode™ brain-computer interface (BCI), or neuroprosthesis.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences in November: Next Generation CAR and T Cell Therapies Conference (Virtual) | Nov . 2-5, 2020 Date/Time: Monday, Nov. 2 at 5:20 p.m. EST Credit Suisse 29th Annual Virtual Healthcare Conference | Nov . 9-12, 2

ARIKAYCE is the First and Only Therapy Approved in Both the European Union and United States for This Difficult-To-Treat Condition

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Jennifer Chien has been appointed as Executive Vice President, Head of North America, effective November 9, 2020. As EVP North America, Ms. Chien will co-lead global integrated commercial strategies in close collaboration with Yann Mazabraud, who

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech,” or “the Company”) is pleased to announce that the launch of a larger consumer product test to further prove the efficacy of the Company’s shampoo on dermatitis and dandruff began on October 14, 2020.

R1 RCM Inc. (NASDAQ:RCM), a leader in technology-enabled revenue cycle management (RCM) services to healthcare providers, and LifePoint Health, a national network of hospitals, post-acute services, outpatient centers and providers in more than 80 locations, have entered into a new revenue cycle management agreement that will make R1 the exclusive revenue cycle management partner for more than one-third of LifePoint hospitals

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2020, on Thursday, November 5, 2020, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Thursday, November 5 th @ 8:30am

Targovax ASA, a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, announces the formation of a new Scientific Advisory Board.